Arkolith/Insider Trading/RGLS/Form 4

Aker Christopher Ray

Sr. VP & General CounselRegulus Therapeutics Inc. (RGLS) · full profile →Form 4 · filed Jun 27, 2025
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
13
2 non-derivative · 11 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Jun 25, 2025Disposed to issuer(D)83K——0
Jun 25, 2025Tender(U)61K——83K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Jun 25, 2025Disposed to issuer(D)3K——0
Jun 25, 2025Disposed to issuer(D)750——0
Jun 25, 2025Disposed to issuer(D)34K——0
Jun 25, 2025Disposed to issuer(D)21K——0
Jun 25, 2025Disposed to issuer(D)48K——0
Jun 25, 2025Disposed to issuer(D)7K——0
Jun 25, 2025Disposed to issuer(D)45K——0
Jun 25, 2025Disposed to issuer(D)394K——0
Jun 25, 2025Disposed to issuer(D)70K——0
Jun 25, 2025Disposed to issuer(D)363K——0
Jun 25, 2025Disposed to issuer(D)488K——0

Transaction Codes

D
Disposition to the issuer
U
See SEC Form 4 code table

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0000950170-25-091019) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML